A Phase 3 interventional study of Chloroprocaine HCl 2% and Ropivacaine 0.75% in Axillary Nerve Block, sponsored by Sintetica SA. Completed at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-15.
Sponsored by Sintetica SA · Phase 3, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries Successful block: anaesthesia adequate for the surgery without any supplementation in the first 45 min.
This Study evaluate the non-inferiority of Test product (Chloroprocaine 2%) versus Reference product (Ropivacaine 0.75%) in terms of proportion of subjects with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min (see definitions below), calculated from the time of readiness for surgery (complete sensory block). Successful block: anaesthesia adequate for the surgery (complete sensory block), without any supplementation in the first 45 min (even if surgery lasts for > 45 min), calculated from the time of readiness for surgery (complete sensory block). Supplementation: i.v. premedication or general anaesthesia or pre- or intra-operative systemic analgesia or additional local anaesthetic infiltration
Sintetica SA is the lead sponsor of 11 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chloroprocaine 2 % Solution for injection, single administration by axillary nerve route 20 mL
Drug: Chloroprocaine HCl 2%
Ropivacaine 0.75% Solution for injection, single administration by axillary nerve route 20 mL
Drug: Ropivacaine 0.75%
Single Administration (20mL) by Axillary Nerve Route
Also known as: Ampres
Single Administration (20mL) by Axillary Nerve Route
Also known as: Naropin
Percentage of Participants With Successful Block for Distal Upper Limb Surgeries
Percentage of patients with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min, calculated from the time of readiness for surgery (complete sensory block).
Time frame: 45 min from the time of readiness of surgery
Time to Onset of Sensory Block (Corresponding to Readiness for Surgery)
Time period from completion of the final perineural injection (time 0 h) to achievement of sensory block in the 4 nerve territories
Time frame: Up to 1 h after last perineural injection
Time to Onset of Motor Block
Time period from completion of the final perineural injection (time 0 h) to achievement of motor block
Time frame: Up to 1 h after last perineural injection
Time to Regression of Sensory Block
Will be deemed to have occurred when cold sensation and sensitive perception have returned (if assessable) in any nerve territory
Time frame: Up to 12 hrs after surgery
Time to Regression of Motor Block
Will be deemed to have occurred when motor score is ≥ 3 (Modified Bromage scale) in any nerve territory (Modified Bromage scale: 0-No movement in relevant muscle group,1-Flicker of movement in relevant muscle group,2-Ability to move relevant muscle group against gravity but inability to move against resistance,3-Reduced power but ability to move muscle group against resistance,4-Full power in relevant muscle group)
Time frame: Up to 12 hrs after surgery
Partecipants Received Rescue Anaesthesia or Rescue Analgesia
partecipants received rescue anaesthesia or rescue analgesia from completion of the final perineural injection (time 0 hour) to administration of first rescue anaesthesia or analgesia (supplementation)
Time frame: 45 min from the time of readiness of surgery
Number of Subjects Who Received Post-operative Analgesia
Number of subjects who received the first post-operative analgesia
Time frame: From surgery day to 24 hrs post surgery
Time to Eligibility for Home Discharge
Time from completion of the final perineural injection (time 0 h) to the time when the criteria for discharge are met, even if, according to the hospital procedures, the patient is discharged from the hospital at a later time
Time frame: from surgery day to 24h post surgery
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Number of Participants with Treatment-emergent Adverse Events (TEAEs) occurring or worsening after the first dose of IMP
Time frame: from surgery day to day 6 +/- 1 after surgery
Neurological Symptoms
Number of patients with Neurological Symptoms (e.g. paraesthesia, motor function problems and pain at the injection site)
Time frame: from surgery day to day 6 +/- 1 after surgery
Heart Rate
The following normal ranges Heart Rate parameters will be used: 50-90 beats/min
Time frame: from surgery day to 24 hrs post surgery
Blood Pressure
The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg
Time frame: from surgery day to 24 hrs post surgery
SpO2
The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%
Time frame: from surgery day to 24 hrs post surgery
Number of Participants With Normal Electrocardiogram (ECG) Parameters
Number of Participants with Normal Electrocardiogram (ECG) Parameters. The following normal ranges ECG parameters will be used: Heart Rate: 50-90 beats/min PR Interval: 100-220 msec QRS Duration: ≤ 120 msec QT Interval: ≤ 500 msec
Time frame: from surgery day to 24 hrs post surgery
From April 2015 to May 2017 in Medical clinic and Hospital
| Milestone | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Started | 106 | 105 |
| Completed | 106 | 105 |
| Not completed | 0 | 0 |
Percentage of patients with a successful block for distal upper limb surgeries, without any supplementation in the first 45 min, calculated from the time of readiness for surgery (complete sensory block).
| Participants | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Percentage of Participants With Successful Block for Distal Upper Limb Surgeries | 96 | 97 |
Time period from completion of the final perineural injection (time 0 h) to achievement of sensory block in the 4 nerve territories
| minutes | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Time to Onset of Sensory Block (Corresponding to Readiness for Surgery) | 10 (10 to 15) | 15 (10 to 15) |
Time period from completion of the final perineural injection (time 0 h) to achievement of motor block
| minutes | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Time to Onset of Motor Block | 10 (5 to 10) | 10 (5 to 10) |
Will be deemed to have occurred when cold sensation and sensitive perception have returned (if assessable) in any nerve territory
| minutes | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Time to Regression of Sensory Block | 68 (64 to 75) | 451 (413 to 480) |
Will be deemed to have occurred when motor score is ≥ 3 (Modified Bromage scale) in any nerve territory (Modified Bromage scale: 0-No movement in relevant muscle group,1-Flicker of movement in relevant muscle group,2-Ability to move relevant muscle group against gravity but inability to move against resistance,3-Reduced power but ability to move muscle group against resistance,4-Full power in relevant muscle group)
| minutes | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Time to Regression of Motor Block | 65 (60 to 69) | 415 (388 to 460) |
partecipants received rescue anaesthesia or rescue analgesia from completion of the final perineural injection (time 0 hour) to administration of first rescue anaesthesia or analgesia (supplementation)
| Participants | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Partecipants Received Rescue Anaesthesia or Rescue Analgesia | 9 | 7 |
Number of subjects who received the first post-operative analgesia
| Participants | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Number of Subjects Who Received Post-operative Analgesia | 49 | 46 |
Time from completion of the final perineural injection (time 0 h) to the time when the criteria for discharge are met, even if, according to the hospital procedures, the patient is discharged from the hospital at a later time
| minutes | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Time to Eligibility for Home Discharge | 161 (155 to 170) | 355.5 (260 to 450) |
Number of Participants with Treatment-emergent Adverse Events (TEAEs) occurring or worsening after the first dose of IMP
| Participants | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 58 | 76 |
Number of patients with Neurological Symptoms (e.g. paraesthesia, motor function problems and pain at the injection site)
| Participants | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| burning : discharge | 8 | 1 |
| burning : day 7 | 6 | 4 |
| tingling : discharge | 8 | 25 |
| tingling : day 7 | 5 | 6 |
| Pins and needles sensation : discharge | 1 | 5 |
| Pins and needles sensation : day 7 | 2 | 0 |
| Pricking : discharge | 8 | 5 |
| Pricking : day 7 | 0 | 0 |
| aching : discharge | 10 | 6 |
| aching : day 7 | 4 | 3 |
| numbness : discharge | 2 | 27 |
| numbness : day 7 | 2 | 3 |
| hypoesthesia : discharge | 5 | 14 |
| hypoesthesia : day 7 | 5 | 5 |
| Pain surgery site : discharge | 0 | 1 |
| Pain surgery site : day 7 | 0 | 0 |
| diffuse hair loss : discharge | 0 | 0 |
| diffuse hair loss : day 7 | 0 | 1 |
| headache : discharge | 0 | 0 |
| headache : day 7 | 2 | 0 |
| itching : discharge | 0 | 0 |
| itching : day 7 | 0 | 1 |
The following normal ranges Heart Rate parameters will be used: 50-90 beats/min
| beats/minutes | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| screening | 73 ± 12 | 73.6 ± 12.3 |
| baseline | 72.5 ± 10.8 | 71.6 ± 12.5 |
| discharge | 71.5 ± 11.5 | 73 ± 12.3 |
The following normal ranges Systolic and Diastolic Blood Pressure parameters will be used: Systolic Blood Pressure: 100-139 mmHg Diastolic Blood Pressure: 50-89 mmHg
| mmHg | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Systolic Blood Pressure at screening | 137 ± 20.5 | 136.2 ± 18.2 |
| Systolic Blood Pressure at baseline | 136.6 ± 18.9 | 138 ± 19.1 |
| Systolic Blood Pressure at discharge | 130.5 ± 17.8 | 130.1 ± 17.3 |
| Diastolic Blood Pressure at screening | 80.8 ± 11.4 | 80.5 ± 9.8 |
| Diastolic Blood Pressure at baseline | 78.2 ± 10.7 | 80.1 ± 10.4 |
| Diastolic Blood Pressure at discharge | 74.4 ± 11.1 | 75.4 ± 9.8 |
The following normal ranges SpO2 parameters will be used: Peripheral Oxygen Saturation: ≥ 95%
| percentage of SpO2 | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| baseline | 97.05 ± 1.51 | 97.36 ± 1.69 |
| discharge | 97.47 ± 1.52 | 97.61 ± 1.33 |
Number of Participants with Normal Electrocardiogram (ECG) Parameters. The following normal ranges ECG parameters will be used: Heart Rate: 50-90 beats/min PR Interval: 100-220 msec QRS Duration: ≤ 120 msec QT Interval: ≤ 500 msec
| Participants | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Number of Participants With Normal Electrocardiogram (ECG) Parameters | 105 | 104 |
Collected over 7 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Chloroprocaine HCl 2% (20 mg/mL) | 0/106 (0%) | 0/106 (0%) | 58/106 (54.7%) |
| Ropivacaine 0.75% (7.5 mg/mL) | 0/105 (0%) | 0/105 (0%) | 76/105 (72.4%) |
| Event | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) |
|---|---|---|
| Procedural painInjury, poisoning and procedural complications | 48/106 | 41/105 |
| HypoaestesiaNervous system disorders | 9/106 | 38/105 |
| ParaestesiaNervous system disorders | 17/106 | 28/105 |
| burning sensationNervous system disorders | 11/106 | 5/105 |
| pain in extremityMusculoskeletal and connective tissue disorders | 11/106 | 5/105 |
| injection site painGeneral disorders | 6/106 | 5/105 |
| nauseaGastrointestinal disorders | 1/106 | 4/105 |
| headacheNervous system disorders | 3/106 | 1/105 |
| sensorimotor disorderNervous system disorders | 0/106 | 1/105 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/106 | 1/105 |
211 patients were enrolled in the study. 106 of the enrolled patients were randomised to the Test treatment group and 105 patients to the Reference treatment group.
| Age, Continuous(years) | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) | Total |
|---|---|---|---|
| Mean | 55.4 ± 15.4 | 52.6 ± 18.7 | 54 ± 17.1 |
| Sex: Female, Male(Participants) | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) | Total |
|---|---|---|---|
| Female | 71 | 60 | 131 |
| Male | 35 | 45 | 80 |
| Race (NIH/OMB)(Participants) | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 104 | 101 | 205 |
| More than one race | 1 | 1 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) | Total |
|---|---|---|---|
| Austria | 62 | 62 | 124 |
| Switzerland | 44 | 43 | 87 |
| Body Mass Index(kg/m^2) | Chloroprocaine HCl 2% (20 mg/mL) | Ropivacaine 0.75% (7.5 mg/mL) | Total |
|---|---|---|---|
| Mean | 25.58 ± 3.83 | 25.61 ± 3.55 | 25.60 ± 3.69 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2015 to primary completion in May 2017, 25 months.
Results were first posted in Jul 2021, 4 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Chloroprocaine
Sintetica SA